First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) — Cash Flow-to-Debt Ratio
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a Cash Flow-to-Debt Ratio of -2.50x as of December 2024, meaning its operating cash flow of $-125.81 Million could theoretically repay -3% of its total liabilities ($50.30 Million) in one year. See working capital to net assets of First Tracks Biotherapeutics, Inc. Ordin to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow-to-Debt Ratio (2023–2024)
Historical debt coverage capacity for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued across 2 annual periods. Also explore First Tracks Biotherapeutics, Inc. Ordin equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Year-by-year debt coverage analysis for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued. For market capitalisation and broader financial context, see First Tracks Biotherapeutics, Inc. Ordin stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.50x | $-125.81 Million | $50.30 Million | ▲ +7.9% |
| 2023 | -2.71x | $-93.00 Million | $34.26 Million | — |